Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wenbin Jin

Showing results (41-50 of 43) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 43 results.
Microbiological Research|August 25, 2024
Repurposing cetylpyridinium chloride and domiphen bromide as phosphoethanolamine transferase inhibitor to combat colistin-resistant EnterobacteralesChen Xu, Qipeng Cheng, Kaichao Chen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 24, 2024
Comparison of novel PSMA-targeting [<sup>177</sup>Lu]Lu-P17-087 with its albumin binding derivative [<sup>177</sup>Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human studyLinlin Li, Jiarou Wang, Guochang Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 17, 2024
First-in-human study of dosimetry, safety and efficacy for [<sup>177</sup>Lu]Lu-P15-073: a novel bisphosphonate-based radioligand therapy (RLT) agent for bone metastasesRuiyue Zhao, Jie Lv, Mingzhao Li, et al.
Pageof 5

Showing results (41-50 of 43) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 43 results.
Microbiological Research|August 25, 2024
Repurposing cetylpyridinium chloride and domiphen bromide as phosphoethanolamine transferase inhibitor to combat colistin-resistant EnterobacteralesChen Xu, Qipeng Cheng, Kaichao Chen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 24, 2024
Comparison of novel PSMA-targeting [<sup>177</sup>Lu]Lu-P17-087 with its albumin binding derivative [<sup>177</sup>Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human studyLinlin Li, Jiarou Wang, Guochang Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 17, 2024
First-in-human study of dosimetry, safety and efficacy for [<sup>177</sup>Lu]Lu-P15-073: a novel bisphosphonate-based radioligand therapy (RLT) agent for bone metastasesRuiyue Zhao, Jie Lv, Mingzhao Li, et al.
Pageof 5